# Roche builds blockbuster BTK case for fenebrutinib in multiple sclerosis as FDA decision approaches

> **Open Intelligence Dossier** · First detected: 2026-10-22 10:20 UTC · Category: Business

## Executive Summary
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

## Intelligence Brief
&quot;Roche builds blockbuster BTK case for fenebrutinib in multiple sclerosis as FDA decision approaches&quot; is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.


Outlets currently covering the story include marketscreener.com, Stock Titan, Business Wire and Reuters. PULSE measures a story&#039;s velocity from how quickly new articles appear and how many independent newsrooms join the coverage.


This brief was generated by PULSE&#039;s extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| marketscreener.com | Roche unveils data as Berenberg reviews outlook ahead of quarterly results | [Source Link](https://news.google.com/rss/articles/CBMixgFBVV95cUxOUkN1T29vZEpneFZGSVVfU1hLR2gzOVc4bFRjTjFZMzViQnI4THZYVjU0b2ZnQ2laX0tPMGs1OEh4QnR3ZkFULXpURExWUkFTMmYyQU0zLU5SUjEtQ2drQ3VIUlBWMlFkQzZGTXZkRklicDBlQ1ZnaXVTZHlMeGhuZy1qR1MyVE1HSGZTdGY5SVZseENHNHd2cVoxcGxHSm5aVC1QdWlJM0NQU1kwSjA1X1owNTVRSXpmZXRQaGdha2pGYnJQYVE?oc=5) |
| Stock Titan | All 14 patients in Tiziana’s multiple sclerosis access program had stable or improved disease within six months. | [Source Link](https://news.google.com/rss/articles/CBMiuwFBVV95cUxOMndJUERweFd5UE9XbUdnWW9oaTNoN1RESkpaYXRKRld4UF9RTzNBcU4xVFJraDBoc21HcXoxQVVpVEFUeFhDZDRmdmNHLTA1WDlIRk5jY0RjaUNtQm85ZmVhQnhyeUp3TGlaZFhMNjF5ZXZrMDVTdVppSUV4VkxZZlpLQzhheE9mdWp2elFQNmUxaGxmRWNxUlBUSlRzUzhnZkFiUnpSMnNlTWJRa3dBd3pjY1ZmUklkSHBN?oc=5) |
| Business Wire | Genentech Presents New Pivotal Trial Data Across Broad Neuroimmunology Portfolio at MSToronto2026 | [Source Link](https://news.google.com/rss/articles/CBMi6gFBVV95cUxPNm1xWDI5T2VDM3dwdXVpd0VuTElFOHptV0lrZkNyd1lmb2otVlR6T3JFTTdvSHBGLWdXSzJpZnhVanNGR3JndUhpX3h5d212cThXMC1VZmdHd0Q4eWlxVm1pOFYwcnNFcHR4cm9GS2RUTENDSkhld3VhRmVLMlU3enZySHZ4Zm1ndjdqenlUNjhtNVRITUFiUUxMZk1ZZE9WTzFHUHFXdlV5TVZTalV2MG1YaVZQU21TenU1TzhEZUlyNVlObU0tTjlfVk1yaW9mM1NrMHh0Zm1mSkNxYktXOWlIcnE2cUtGNWc?oc=5) |
| Reuters | Roche says experimental MS pill cuts relapses by 55% in late-stage trials | [Source Link](https://news.google.com/rss/articles/CBMi2AFBVV95cUxQNk5IS25oQ0x3RW5Ld0NXbW5mOENjNFlXTFd3TDNEaVNOU0NhazZBM3ZQTkJHekNHRGZsR2lRV0J2X3lBb2RFVV92TDF6WlRWQ2UzclhZNzQ4bTVpUkJTRXNBcEhSWnB6UDNoX050MnpMdldSelV2UDNXcnFOQkdFYWJlQ08xZUFfLUxvSGdTMlJsbzNwdlAzbEppcnNlUGs1TnNpUGF6X0dKWmVyeHNGUmUxay1LTUpQMGUydzBQbGkwaWJLcmdmOGpXaUl5dFNhTDBCa2tVNEE?oc=5) |
| Fierce Biotech | Roche builds blockbuster BTK case for fenebrutinib in multiple sclerosis as FDA decision approaches | [Source Link](https://news.google.com/rss/articles/CBMitAFBVV95cUxOOWs4Qmd1QzFZSU40eU1NMDduQkZtOUF2ZlZ6RzQ2MjB4MWY5Tkh0OVNhQVhrMHlVTnQ4MGhpckZsRENDZ2dkR2JlNnAtUVRPVVFIemtOUG1YUTZQVm1lVnAyaUR5UGNvampSbHlRbmpMZUNxbU9rSWd0STRZVTBkY3RObXFVTUpCZGNWS0RtZWxNaWkwMUkxWU1XeGYwVXE5dTZKaVE3dUtILXM5eEpyWURHNHA?oc=5) |

---
*Canonical Source: https://pulse.byoaiapps.com/trend/2026-10-22/roche-builds-blockbuster-btk-case-for-fenebrutinib-in-multiple-sclerosis-as-fda*
